Credence Genomics
Seoul, South Korea· Est.
AI‑driven NGS platform for comprehensive, rapid pathogen detection and antimicrobial‑resistance profiling.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven NGS platform for comprehensive, rapid pathogen detection and antimicrobial‑resistance profiling.
Infectious Diseases
Technology Platform
Proprietary AIoS™ (AI on sequencing) and MMR™ (machine modeling resistance) integrated with long‑read metagenomic sequencing and machine‑learning pipelines for rapid, high‑precision pathogen identification and resistance profiling.
Opportunities
Expansion into outpatient antimicrobial‑stewardship programs and broader health‑system partnerships can increase market penetration and recurring revenue streams.
Risk Factors
Regulatory approval, reimbursement uncertainty, and competition from larger NGS diagnostic firms could limit adoption and scalability.
Competitive Landscape
Competes with Illumina IDbyDNA, Oxford Nanopore, and AI‑driven diagnostic startups; differentiation hinges on integrated long‑read sequencing and proprietary AI/ML models delivering faster, high‑precision results.